Literature DB >> 11385497

A dominant-negative therapy for anthrax.

S H Leppla.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385497     DOI: 10.1038/89025

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  6 in total

1.  Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors:  Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Evaluation of combinatorial vaccines against anthrax and plague in a murine model.

Authors:  Amanda B DuBois; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

3.  Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Authors:  Jason E Comer; Ashok K Chopra; Johnny W Peterson; Rolf König
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Effects of introducing a single charged residue into the phenylalanine clamp of multimeric anthrax protective antigen.

Authors:  Blythe E Janowiak; Audrey Fischer; R John Collier
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

5.  Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.

Authors:  Anna U Bielinska; Katarzyna W Janczak; Jeffrey J Landers; Paul Makidon; Laurie E Sower; Johnny W Peterson; James R Baker
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

Review 6.  Inhibition of Pore-Forming Proteins.

Authors:  Neža Omersa; Marjetka Podobnik; Gregor Anderluh
Journal:  Toxins (Basel)       Date:  2019-09-19       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.